December 5, 2023 – 3:36 PM UTC
(Reuters) – Eli Lilly (LLY.N) said on Tuesday its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price.
Advertisement
Zepbound is the latest entrant to the fast-growing market for weight-loss drugs, which is expected to grow to about $100 billion by the end of the decade.
Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024. Novo Nordisk’s powerful obesity drug Wegovy is expected to make $7.3 billion in sales next year, according to Barclays analyst Emily Field.
Both medicines are GLP-1 agonists, a class originally designed to treat type 2 diabetes.
Zepbound was added to the U.S. list of preferred medicines by at least one major drug benefits company, Cigna…
